0
     

Report Added
Report already added
Global Emerging Therapeutics for Hematological Malignancies Market 2022 - Industry Briefing

Global Emerging Therapeutics for Hematological Malignancies Market 2022 - Industry Briefing

The global emerging therapeutics for hematological malignancies market is anticipated to increase by USD 12.0 billion till 2028 at an average annual growth of 13.4 percent as per the latest report by Gen Consulting Company.

This industry report offers market estimates of the global market, followed by a detailed analysis of the type, indication, and region. The global market data on emerging therapeutics for hematological malignancies can be segmented by type: CAR T-cell therapies, monoclonal antibodies. The monoclonal antibodies segment was the largest contributor to the global emerging therapeutics for hematological malignancies market in 2021. Emerging therapeutics for hematological malignancies market is further segmented by indication: leukemia, lymphoma, multiple myeloma. Based on region, the emerging therapeutics for hematological malignancies market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).

The CAR T-cell therapies market is further segmented into tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), others. Furthermore, the monoclonal antibodies market has been categorized into blinatumomab (Blincyto), brentuximab vedotin (Adcetris), daratumumab (Darzalex), inotuzumab ozogamicin (Besponsa), obinutuzumab (Gazyva), sintilimab (Tyvyt), others.

The global emerging therapeutics for hematological malignancies market is highly competitive. Top players covered in Global Emerging Therapeutics for Hematological Malignancies Market Study are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
- Get a detailed picture of the Global Emerging Therapeutics for Hematological Malignancies Market
- Identify segments/areas to invest in over the forecast period in the Global Emerging Therapeutics for Hematological Malignancies Market
- Understand the competitive environment, the market’s leading players
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
Table of Contents

Part 1. Summary
Part 2. Introduction
· Study period
· Geographical scope
· Market segmentation
Part 3. Emerging therapeutics for hematological malignancies market overview
Part 4. Market breakdown by type
· CAR T-cell therapies
· Monoclonal antibodies
Part 5. Market breakdown by indication
· Leukemia
· Lymphoma
· Multiple myeloma
Part 6. Market breakdown by region
· Asia Pacific
· Europe
· North America
· Rest of the World (RoW)
Part 7. Key companies
· AbbVie Inc.
· Amgen Inc.
· Bristol-Myers Squibb Company (BMS)
· F. Hoffmann-La Roche AG
· Gilead Sciences, Inc.
· GlaxoSmithKline plc
· Immune-Onc Therapeutics, Inc.
· Johnson & Johnson
· Merck & Co., Inc.
· Novartis AG
· Pfizer Inc.
· Sanofi S.A.
· Takeda Pharmaceutical Company Limited
Part 8. Methodology

Report Title: Global Emerging Therapeutics for Hematological Malignancies Market 2022 - Industry Briefing


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW